Waters New Rapid Screening-DSC Enables Up to 24x Faster Thermal Stability Testing at Ultra-Low Sample Volumes for Antibody Drugs
Waters (NYSE: WAT) has launched the TA Instruments™ Rapid Screening-Differential Scanning Calorimeter (RS-DSC), a high-throughput device for thermal stability testing of high-concentration biologic formulations. This innovative technology offers up to 24x faster testing and reduces sample volume requirements by 25x compared to competitor capillary DSC technologies.
The RS-DSC utilizes disposable microfluidic chips (MFCs) that enable up to 24 simultaneous measurements, streamlining the testing process for antibody drugs and engineered proteins. It provides more accurate data on high-concentration samples, avoiding the sensitivity challenges of differential scanning fluorescence (DSF) methods. The device also features automated software for rapid and in-depth analysis of thermodynamic properties.
Waters (NYSE: WAT) ha lanciato il Calorimetro Differenziale a Scansione Rapida (RS-DSC) della linea TA Instruments™, un dispositivo ad alta capacità per la verifica della stabilità termica delle formulazioni biologiche ad alta concentrazione. Questa tecnologia innovativa offre fino a 24 volte test più rapidi e riduce i requisiti di volume del campione di 25 volte rispetto alle tecnologie DSC capillari dei concorrenti.
Il RS-DSC utilizza chip microfluidici monouso (MFC) che consentono fino a 24 misurazioni simultanee, semplificando il processo di test per farmaci ad anticorpi e proteine ingegnerizzate. Fornisce dati più accurati su campioni ad alta concentrazione, evitando le sfide di sensibilità dei metodi di fluorescenza a scansione differenziale (DSF). Inoltre, il dispositivo presenta un software automatizzato per un’analisi rapida e approfondita delle proprietà termodinamiche.
Waters (NYSE: WAT) ha lanzado el Calorímetro de Barrido Diferencial de Pantalla Rápida (RS-DSC) de TA Instruments™, un dispositivo de alto rendimiento para la prueba de estabilidad térmica de formulaciones biológicas de alta concentración. Esta tecnología innovadora ofrece hasta 24 veces más rápido en las pruebas y reduce los requisitos de volumen de muestra en 25 veces en comparación con las tecnologías DSC capilares de los competidores.
El RS-DSC utiliza chips microfluídicos desechables (MFC) que permiten hasta 24 mediciones simultáneas, agilizando el proceso de prueba para medicamentos anticuerpo y proteínas diseñadas. Proporciona datos más precisos sobre muestras de alta concentración, evitando los desafíos de sensibilidad de los métodos de fluorescencia de barrido diferencial (DSF). El dispositivo también cuenta con un software automatizado para un análisis rápido y profundo de las propiedades termodinámicas.
Waters (NYSE: WAT)는 TA Instruments™의 급속 스크리닝-차등 스캐닝 칼로리미터(RS-DSC)를 출시했습니다. 이는 고농도 생물학적 제형의 열 안정성 검사를 위한 고처리 장치입니다. 이 혁신적인 기술은 최대 24배 빠른 테스트를 제공하며, 경쟁업체의 모세관 DSC 기술과 비교해 샘플 볼륨 요구 사항을 25배 감소시킵니다.
RS-DSC는 최대 24개의 동시 측정을 가능하게 하는 일회용 마이크로 유체 칩(MFC)을 사용하여 항체 약물과 공학적 단백질에 대한 테스트 프로세스를 간소화합니다. 이는 고농도 샘플에 대한 보다 정확한 데이터를 제공하여 차등 스캐닝 형광(DSF) 방법의 민감도 문제를 피합니다. 또한, 장치는 열역학적 특성에 대한 신속하고 심층적인 분석을 위한 자동화 소프트웨어를 갖추고 있습니다.
Waters (NYSE: WAT) a lancé le Calorimètre de Scanning Différentiel à Rapidité d'Instruments TA™ (RS-DSC), un appareil à haut débit pour les tests de stabilité thermique des formulations biologiques à haute concentration. Cette technologie innovante offre des tests jusqu'à 24 fois plus rapides et réduit les exigences de volume d'échantillon de 25 fois par rapport aux technologies DSC capillaires concurrentes.
Le RS-DSC utilise des puces microfluidiques jetables (MFC) qui permettent jusqu'à 24 mesures simultanées, simplifiant ainsi le processus de test pour les médicaments anticorps et les protéines conçues. Il fournit des données plus précises sur les échantillons à haute concentration, évitant les problèmes de sensibilité des méthodes de fluorescence à balayage différentiel (DSF). L'appareil comprend également un logiciel automatisé pour une analyse rapide et approfondie des propriétés thermodynamiques.
Waters (NYSE: WAT) hat das Rapid Screening-Differential Scanning Calorimeter (RS-DSC) von TA Instruments™ auf den Markt gebracht, ein Hochdurchsatzgerät zur thermischen Stabilitätsprüfung von hochkonzentrierten biologischen Formulierungen. Diese innovative Technologie bietet bis zu 24-mal schnellere Tests und reduziert die Anforderungen an das Probenvolumen um 25-mal im Vergleich zu den DSC-Technologien der Wettbewerber.
Der RS-DSC verwendet disposable Mikrofluidik-Chips (MFCs), die bis zu 24 gleichzeitige Messungen ermöglichen und den Testprozess für Antikörpermedikamente und konstruierte Proteine optimieren. Er liefert genauere Daten zu hochkonzentrierten Proben und vermeidet die Sensitivitätsprobleme der Differential Scanning Fluorescence (DSF) Methoden. Das Gerät verfügt außerdem über eine automatisierte Software für eine schnelle und umfassende Analyse der thermodynamischen Eigenschaften.
- Increases throughput up to 24x compared to competitor capillary DSC technologies
- Reduces sample volume requirements by 25x through advanced microfluidic technologies
- Enables analysis under actual high-concentration drug dosing conditions
- Provides more accurate measurements of high-concentration biological drug formulations
- Features automated software for rapid and in-depth analysis
- None.
Insights
Waters Corporation has introduced the TA Instruments Rapid Screening-Differential Scanning Calorimeter (RS-DSC), a notable advancement in thermal stability testing for biopharmaceutical developers, particularly those focusing on antibody drugs. The need for efficient and precise testing tools is paramount in the biopharmaceutical industry, where time-to-market and drug efficacy are critical factors. This innovation, which enhances throughput by up to 24x compared to existing technologies, offers significant competitive advantages. For investors, this development signals potential revenue growth as the demand for high-concentration injectable drugs rises. The reduction in sample volume requirements and the automated software capabilities also suggest lower operational costs, potentially improving profit margins.
The TA Instruments RS-DSC represents a substantial leap in technological innovation within biopharmaceutical testing. Leveraging advanced microfluidic technologies, this product significantly reduces sample volume requirements by 25x, which is a game-changer for laboratories and research facilities. The disposable microfluidic chips (MFCs) streamline the process, minimizing contamination risks and eliminating the need for repetitive cleaning. Additionally, the high throughput capability, enabling up to 24 simultaneous measurements, maximizes efficiency and accelerates drug development timelines. For tech-savvy investors, this product showcases Waters Corporation's ability to integrate cutting-edge technology with practical applications in drug development, making it a valuable asset in the growing biopharmaceutical market.
From a financial perspective, the launch of the TA Instruments RS-DSC could have a profound impact on Waters Corporation's revenue streams. The product's ability to meet the increasing demand for high-concentration injectable drugs positions it well within a lucrative market segment. The advanced features of the RS-DSC, including its high throughput and reduced sample volume requirements, are likely to attract a broad range of biopharmaceutical clients. This could lead to increased sales and market share for Waters Corporation. Furthermore, the efficiency gains and potential cost savings from reduced operational requirements may enhance the company's profitability. Investors should monitor subsequent sales performance and market adoption rates to gauge the financial impact accurately.
News Summary:
- Reduces sample volume requirements by 25x through use of advanced microfluidic technologies while increasing throughput up to 24x compared with competitor capillary DSC technologiesi.
- Streamlines thermal stability testing of biologics using disposable microfluidic chips (MFCs) enabling analysis under actual high-concentration drug dosing and use conditions.
- Delivers faster and more accurate measurements of high-concentration biological drug formulationsii with unique design that simplifies sample preparation and accelerates drug development.
"Demand is increasing for higher concentration injectable drugs, and biologic developers are looking for stability testing that is fast and efficient," said Jianqing Bennett, Waters Corporation Senior Vice President of the TA Instruments Division. "Our new Rapid Screening-DSC meets these needs by providing a high-throughput alternative to existing capillary DSCs and a more reliable and accurate option to differential scanning fluorescence (DSF) technologies."
The TA Instruments RS-DSC offers a more convenient and accurate solution to assess biological drug stability and quality by employing disposable, low sample volume microfluidic chips (MFCs) that enable up to 24 simultaneous measurements. This reduces or eliminates the need for sample dilution, repetitive instrument cleaning, and lowers contamination risk. Its unique design avoids the sensitivity challenges of DSF methods, enabling it to produce more accurate dataiii on high-concentration samples.
Additionally, the TA Instruments RS-DSC features state-of-the-art automated software that provides rapid, effortless, precise, and in-depth insights about a sample's thermodynamic properties.
The TA Instruments RS-DSC is now available globally to all customers through the TA Instruments Division of Waters Corporation.
Additional Resources
- Learn more about the TA Instruments Rapid Screening-Differential Scanning Calorimeter
- TA Instruments Rapid Screening-DSC Application Notes:
- Follow and connect with the Waters TA Instruments Division via LinkedIn, Twitter/X, and Facebook
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,700 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.
Waters and TA Instruments are trademarks of Waters Technologies Corporation. |
Contact:
Laura Borland, TA Instruments Corporate Communications
Waters Corporation
laura_borland@waters.com
+1.302.367.6958
i As compared to capillary DSC offered by a leading in-market competitor. Comparison based on published specifications – the TA Instruments RS-DSC can perform 24 test runs for every one run on the competing capillary DSC instrument, which also operates at a nearly 25x higher sample volume (250 uL) over that of the TA Instruments RS-DSC (11uL). |
View original content to download multimedia:https://www.prnewswire.com/news-releases/waters-new-rapid-screening-dsc-enables-up-to-24x-faster-thermal-stability-testing-at-ultra-low-sample-volumes-for-antibody-drugs-302202249.html
SOURCE Waters Corporation
FAQ
What is the key feature of Waters' new TA Instruments RS-DSC?
How does the TA Instruments RS-DSC improve biopharmaceutical testing?
When was the TA Instruments RS-DSC released by Waters (WAT)?
What advantages does the TA Instruments RS-DSC offer over DSF technologies?
